NIH R01 · 2025
PROJECT SUMMARY Immune checkpoint blockade (ICB) therapies such as PD1/PD-L1-targeting antibodies activate the immune system to help eradicate tumor cells. However, treatment response varies dramatically across patients and cancer types. Genetic defects in DNA damage response pathways predispose to cancer and strongly influence tumor immunity. Our long-term goal is to understand how defects in DNA repair shape immunotherapy efficacy. A very important and commonly altered DNA repair pathway in human tumors is homologous recombination (HR) repair. The impact of mutations in this major repair pathway on tumor immunity is poorly understood and is an area of urgent need. Our preliminary data…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.